Christina Stoller
Internal Medicine · Moline, ILNPI 1366172645
Payments from drug & device makers
Across 237 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$352
- GSK$345
- Novo Nordisk$286
- Pfizer$226
- Boehringer Ingelheim$213
- plus $2K from 36 others
What the payments were for
- Food & beverage$4,29995%
- Education$2265%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,525 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $45,313 |
| JardianceEmpagliflozin | 32 | $40,888 |
| EliquisApixaban | 49 | $39,592 |
| OzempicSemaglutide | 26 | $34,405 |
| RybelsusSemaglutide | 15 | $29,161 |
| Spiriva RespimatTiotropium Bromide | 12 | $18,268 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $17,544 |
| LinzessLinaclotide | 18 | $17,143 |
| ZenpepLipase/Protease/Amylase | 17 | $15,022 |
| MounjaroTirzepatide | 13 | $14,040 |
| FarxigaDapagliflozin Propanediol | 12 | $9,126 |
| Repatha SureclickEvolocumab | 13 | $8,099 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $3,017 |
| Gabapentin | 116 | $2,591 |
| Levothyroxine Sodium | 129 | $1,555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $286 | $63,56641 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $213 | $59,15644 claims |
| GSKTrelegy Ellipta | $345 | $45,31339 claims |
| PfizerEliquis | $226 | $39,59249 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,027 | $26,67125 claims |
| AbbVieLinzess | $352 | $17,14318 claims |
| Aimmune Therapeutics, Inc.Zenpep | $31 | $15,02217 claims |
| Lilly USA, LLCMounjaro | $195 | $14,04013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Moline
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
- Yoko MomoyamaLombard$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.